Avoiding Hypotension in Preterm Neonates
- Conditions
- Hypotension
- Registration Number
- NCT01910467
- Lead Sponsor
- Medical University of Graz
- Brief Summary
Objectives Firstly to examine in preterm neonates, whether it is possible to reduce number of hypotensive episodes and use of catecholamines by applying cerebral/peripheral near infrared spectroscopy in combination with predefined interventions and secondly to explore the potential impact on cerebral injury and mortality.
Hypothesis By using predefined interventions for changes in cerebral/peripheral oxygenation ratio investigators will reduce hypotensive episodes and use of catecholamines which will reduce cerebral injury and mortality.
Methods Cerebral (cTOI) and peripheral-muscle (pTOI) tissue-oxygenation-index (NIRO 300) will be measured for 24h starting \<6 hours postpartum. When cTOI/pTOI ratio increases \>5% within a 6h period, predefined interventions will be performed.
Primary outcome parameter will be duration of hypotensive episodes and use of catecholamines during the first 48h after birth. Secondary outcome parameters will be cerebral injury and mortality.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 98
- preterm neonates
- decision to conduct full life support
- written informed consent
- age <6 hours
- no use of catecholamines before start of NIRS measurements
- no decision to conduct full life support
- no written informed consent
- age >6 hours
- use of catecholamines before start of NIRS measurements
- congenital malformation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Time (percentage of hours) of hypotension/use of catecholamines during the first 48 hours 48 hours
- Secondary Outcome Measures
Name Time Method Cerebral injury by cerebral ultrasound up to 16 weeks From date of randomization until the date of discharge or date of 40 weeks of gestational age, whichever came first, assessed up to 16 weeks.
Mortality up to 16 weeks
Trial Locations
- Locations (1)
Dep. of Pediatrics, Medical University of Graz
🇦🇹Graz, Styria, Austria
Dep. of Pediatrics, Medical University of Graz🇦🇹Graz, Styria, Austria